• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Rare Disease : Episode 15

Episode 16 - Factors Hindering Care for SLE Patients

Video

Despite the number of drugs currently in the pipeline for the treatment of systemic lupus erythematosus (SLE), the panelists raise concerns about unaddressed factors that may continue to impede a clinician’s decision to recommend a treatment option to a patient.

Michelle Petri, MD, MPH, explains that newly-approved therapy options still lack personalized biomarkers and do not provide important long-term outcomes data that help professionals make decisions about treatment for patients with SLE.

Patrick F. Fogarty, MD, further explains that when defining the value of medical therapy, an economic consideration continues to stand in the way of treatment recommendations.

Without addressing these issues, Dr Petri and Dr Fogarty agree that when selecting appropriate therapy for a patient, and when considering the costs associated with a treatment option, it is important to individualize therapy for patients with SLE.


Related Videos
Leslie Fish, PharmD.
Ronesh Sinha, MD
Beau Raymond, MD
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Pat Van Burkleo
Pat Van Burkleo
dr robert sidbury
dr mitzi joi williams
dr krystyn van vliet
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.